MarketPeel
Insider Trading Intelligence
JL

James E. Levine

KZIA
CHIEF FINANCIAL OFFICER · KAZIA THERAPEUTICS LTD · CIK 0001463151
FILING MIX · LIFETIME100%/0%
BUYS
15
SELLS
0
TOTAL VALUE
$277.4K
COMPANIES
2
ACTIVE SINCE
Jul 2021
HOLDINGS NOW
1,495,117
AVG SELL PX
TRADE KIND
SHOWING 15 / 15
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
9 backtested trades · 8 horizons · 3 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by James E. Levine, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d9+66.67%+0.60%-0.72%+1.31%+9.48%
14d9+66.67%+7.23%-1.40%+8.63%+16.85%
30d9+55.56%-4.85%-1.87%-2.97%+8.61%
60d9+11.11%-7.37%+4.01%-11.38%-11.93%
90d9+11.11%-10.23%+1.13%-11.36%-13.28%
180d9+11.11%-37.78%-1.42%-36.37%-56.91%
1y9+11.11%-44.45%+2.25%-46.70%-46.55%
2y9(3 pending)+16.67%-46.96%+11.45%-58.42%-72.67%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
Not enough transaction history to chart holdings.
Trading cadence · quarterly flow
BUY SELL
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 15 buys / 0 sellsCOVERAGE · 20 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
KZIA
KAZIA THERAPEUTICS LTD
PURCHASEGRANT
Stock grant
200,000200,000Jun 19, 2026Jun 23, 2026View →
CRDF
CARDIFF ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
332,6211,295,117Mar 11, 2025Mar 13, 2025View →
CRDF
CARDIFF ONCOLOGY, INC.
PURCHASE
Chief Financial Officer
2,400$5.00$12.0K67,716Dec 18, 2024Dec 18, 2024View →
CRDF
CARDIFF ONCOLOGY, INC.
PURCHASE
Chief Financial Officer
2,752$5.42$14.9K65,316Dec 17, 2024Dec 18, 2024View →
CRDF
CARDIFF ONCOLOGY, INC.
PURCHASE
Chief Financial Officer
2,564$3.83$9.8K62,564Dec 16, 2024Dec 18, 2024View →
CRDF
CARDIFF ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
205,008962,496Mar 7, 2024Mar 7, 2024View →
CRDF
CARDIFF ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
197,472757,488Mar 15, 2023Mar 16, 2023View →
CRDF
CARDIFF ONCOLOGY, INC.
PURCHASE
Chief Financial Officer
30,000$1.56$46.7K60,000Sep 16, 2022Sep 19, 2022View →
CRDF
CARDIFF ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
170,016560,016Mar 9, 2022Mar 10, 2022View →
CRDF
CARDIFF ONCOLOGY, INC.
PURCHASE
Chief Financial Officer
5,000$6.75$33.8K10,000Sep 10, 2021Sep 13, 2021View →
CRDF
CARDIFF ONCOLOGY, INC.
PURCHASE
Chief Financial Officer
5,000$6.32$31.6K30,000Sep 10, 2021Sep 13, 2021View →
CRDF
CARDIFF ONCOLOGY, INC.
PURCHASE
Chief Financial Officer
5,000$6.62$33.1K5,000Sep 10, 2021Sep 13, 2021View →
CRDF
CARDIFF ONCOLOGY, INC.
PURCHASE
Chief Financial Officer
5,000$6.35$31.8K25,000Sep 10, 2021Sep 13, 2021View →
CRDF
CARDIFF ONCOLOGY, INC.
PURCHASE
Chief Financial Officer
10,000$6.38$63.8K20,000Sep 10, 2021Sep 13, 2021View →
CRDF
CARDIFF ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
390,000390,000Jul 12, 2021Jul 12, 2021View →
Other insiders · KZIA
Loading peer insiders…
About this filer
CIK 0001463151
ROLE
Chief Financial Officer
PRIMARY
KZIA
COMPANIES
2
ACTIVE SINCE
Jul 2021
MARKETPEEL · /INSIDER/0001463151DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback